Discovery of FXR/PPARγ dual partial agonist

Area of Science:

• Biochemistry
• Pharmacology
• Hepatology

Background:

• Farnesoid X Receptor (FXR) and Peroxisome Proliferator-Activated Receptor gamma (PPARγ) are key nuclear receptors involved in metabolic regulation.
• Agonists for FXR and PPARγ have been explored as anti-diabetic agents for nonalcoholic fatty liver disease (NAFLD).
• Partial agonists are gaining interest to mitigate adverse effects associated with full agonists.

Purpose of the Study:

• To identify and characterize novel compounds with dual partial agonistic activity for FXR and PPARγ.
• To evaluate the potential of these compounds as therapeutic agents for NAFLD associated with type 2 diabetes mellitus.

Main Methods:

• Synthesis and screening of compounds with a benzimidazole scaffold.
• In vitro assays to determine FXR/PPARγ dual partial agonistic activity.
• Assessment of compound 18's effect on PPARγ phosphorylation and metabolic stability using mouse liver microsome assays.

Main Results:

• Compound 18, featuring a benzimidazole scaffold, demonstrated FXR/PPARγ dual partial agonistic activity.
• Compound 18 reduced cyclin-dependent kinase 5-mediated phosphorylation of PPARγ-Ser273.
• Metabolic stability of compound 18 was confirmed in mouse liver microsome assays.
• No previously reported FXR/PPARγ dual partial agonists exhibit similar biological profiles to compound 18.

Conclusions:

• Compound 18 represents a novel FXR/PPARγ dual partial agonist.
• The unique biological profile of compound 18 suggests its potential as a candidate for treating NAFLD in type 2 diabetes patients.
• This finding opens an unprecedented therapeutic avenue for managing complex metabolic disorders.